Epigenetic Drug Therapy in the Treatment of Colorectal Cancer

Author(s): Seyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Maryam Ghandehari, Sima Seifi, Seyed Mohammad Reza Parizadeh, Mehrdad Moetamani-Ahmadi, Seyed Mahdi Hassanian, Majid Khazaei, Majid Ghayour-Mobarhan, Gordon A. Ferns, Amir Avan*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 23 , 2018

Become EABM
Become Reviewer
Call for Editor


Colorectal Cancer (CRC) is one of the most common cancers with a high rate of morbidity and mortality worldwide. It has been demonstrated that epigenetic alterations which may cause changes in the expression of microRNA, DNA methylation and histone acetylation that results in inheritable modifications in gene expression in colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, targeting epigenetic modification has emerged as a potentially important treatment approach in CRC. The US Food and Drug Association has approved the use of some epigenetic drugs that may be able to inhibit or reverse these alterations and also enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review we have summarized the recent pre-clinical and clinical trial studies investigating the therapeutic value of using epigenetic drugs as novel therapeutic approach in CRC treatment.

Keywords: Epigenetic, colorectal cancer, drug, DNA methylation, microRNA, histone acetylation, chemotherapeutic agents.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 30 July, 2018
Page: [2701 - 2709]
Pages: 9
DOI: 10.2174/1381612824666180730151904
Price: $65

Article Metrics

PDF: 41
PRC: 1